News

Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program

70% of Patients in the Expanded Access Program (EAP) Have Seen Measurable Clinical Improvement in Their Fatigue After Six Months…

2 years ago

BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024

MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for…

2 years ago

RadNet, Inc. Announces Date of its First Quarter 2024 Financial Results Conference Call

LOS ANGELES, April 22, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic…

2 years ago

Evexta Bio Reports Progress towards Clinical Development of Rupitasertib in Advanced Breast Cancer

Evexta Bio Reports Progress towards Clinical Development of Rupitasertib in Advanced Breast Cancer Feedback from FDA following Type B meeting…

2 years ago

Nexstim Receives NBS 6 System Order from Clinic in Florida, US

Press release, Helsinki, 22 April 2024 at 11 AM (EEST) Nexstim Receives NBS 6 System Order from Clinic in Florida,…

2 years ago

Kynos Therapeutics announces positive top-line results from the first-in-human Phase I study of its KMO inhibitor, KNS366, demonstrating safety, tolerability and target engagement

EDINBURGH, United Kingdom, April 22, 2024 (GLOBE NEWSWIRE) -- Kynos Therapeutics Ltd, a clinical-stage biotechnology company developing first-in-class small molecule…

2 years ago

Transactions in Connection with Share Buy-back Program Genmab

Company Announcement COPENHAGEN, Denmark; April 22, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation…

2 years ago

Orion Corporation: Managers’ transactions – Veli-Matti Mattila

ORION CORPORATION MANAGERS’ TRANSACTIONS 22 APRIL 2024 at 9.45 EEST         Orion Corporation: Managers’ transactions – Veli-Matti Mattila Orion Corporation has…

2 years ago

SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients

SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients Phase…

2 years ago